Arcturus Therapeutics Holdings Inc (ARCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $240.96M
Last updated: Nov 17, 2026 at 4:34 PM ET
Arcturus Therapeutics Holdings Inc (ARCT) Statistics
Arcturus Therapeutics Holdings (ARCT) has a market cap of $240.96M and an enterprise value of $56.14M. It kept -285.91% of revenue as net income over the last 12 months. Revenue fell 68.74% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 76.70% below the market cap, as cash exceeds debt.
| Market Cap | $240.96M |
|---|---|
| Enterprise Value | $56.14M |
| Latest price (Nov 17, 2026) | $7.97 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 7.4x and 1.3x. Its year-end P/S ranged from 1.9x to 88.0x from 2017 to 2025.
| P/S Ratio | 7.4x |
|---|---|
| Forward P/S | 8.6x |
| P/B Ratio | 1.3x |
Price Statistics
The stock is up 9.63% over 52 weeks and trades 34.30% below its 50-day average.
| Beta (1Y) | 2.07 |
|---|---|
| 52-Week Change | +9.63% |
| 1-Month Change | -23.51% |
| 3-Month Change | -22.47% |
| 6-Month Change | +19.13% |
| 5-Year Change | -75.46% |
| 10-Year Change | -17.91% |
| Total Return (1Y) | +9.63% |
| Total Return (3Y CAGR) | -31.67% |
| Total Return (5Y CAGR) | -26.76% |
| Return vs SPY (1Y) | +8.83% |
| Max Drawdown (1Y) | -52.92% |
| Max Drawdown (3Y) | -87.54% |
| Sharpe Ratio (1Y) | 0.23 |
| Correlation with SPY (1Y) | 0.36 |
| 50-Day Average | $12.13 |
| 200-Day Average | $9.11 |
| 52-Week Range | $5.50 to $17.96 |
| RSI (14 Days) | 35.2 |
| Average Volume (20 Days) | 674.26K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.68x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.68x |
|---|---|
| Quick Ratio | 6.68x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -51.71% over the last 12 months, against a 5-year average of -32.16%.
| Return on Equity (ROE) | -51.71% |
|---|---|
| Return on Assets (ROA) | -40.52% |
| ROE (5Y Average) | -32.16% |
| ROA (5Y Average) | -20.90% |
| ROIC (5Y Average) | -25.57% |
| Asset Turnover | 0.12x |
| Receivables Turnover | 19.93x |
Scores
ARCT has an Altman Z-Score of -1.19, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.19 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $30.51M over the last 12 months.
| Revenue | $30.51M |
|---|---|
| Revenue Growth (YoY) | -68.74% |
| Gross Profit | $30.51M |
| Operating Income | -$94.97M |
| Pretax Income | -$87.25M |
| Net Income | -$87.24M |
| Reported EPS (TTM) | -$3.08 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 78.36% of the $215.32M in total assets.
| Cash and Equivalents | $184.82M |
|---|---|
| Total Debt | $0 |
| Net Cash | $184.82M |
| Net Cash Per Share | $6.50 |
| Working Capital | $161.05M |
| Shareholder Equity | $168.73M |
| Book Value Per Share | $5.93 |
| Total Assets | $215.32M |
| Total Liabilities | $46.59M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$62.48M |
|---|---|
| FCF Per Share | -$2.20 |
| Depreciation and Amortization | $2.58M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -311.22%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -311.22% |
| Pretax Margin | -285.92% |
| Net Margin | -285.91% |
Growth
Revenue fell 26.43% a year over 3 years.
| Revenue Growth (3Y CAGR) | -26.43% |
|---|---|
| Revenue Growth (5Y CAGR) | +53.78% |
| Book Value Per Share Growth (2Y CAGR) | -13.57% |
| Tangible Book Per Share Growth (2Y CAGR) | -13.57% |
Dividends and Yields
ARCT does not pay a dividend.
| Buyback Yield | -5.26% |
|---|---|
| Shareholder Yield | -5.26% |
Stock Splits
The last split was a 1-for-7 reverse split on Nov 16, 2017.
| Last Split Date | Nov 16, 2017 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:7 |
Peer Position
Against 7 similar companies, ARCT has the 3rd highest P/S.
P/S RatioPeer median 5.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -88.51%
| P/S Ratio | 7.4x vs 5.5x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -68.74% vs -88.51% median |
Analyst Forecast
Consensus estimates put revenue growth at -37.45% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -37.45% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ARCT
What is ARCT's market cap?
Arcturus Therapeutics Holdings has a market cap of $240.96M. Its enterprise value, which adds debt and subtracts cash, is $56.14M.
How many shares of ARCT are outstanding?
Arcturus Therapeutics Holdings has 28.44M shares outstanding. The count is up 4.60% from a year earlier.
Does ARCT pay a dividend?
No. Arcturus Therapeutics Holdings does not pay a dividend.
How much debt does ARCT have?
Arcturus Therapeutics Holdings has $0 of total debt and $184.82M of cash and equivalents, a net cash position of $184.82M.
ARCT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors